Anzurstobart

Description: Anzurstobart, a fully human monoclonal anti-SIRPalpha antibody, is characterized by high-affinity binding and inhibition of the CD47-SIRPalpha interaction, which is known to suppress macrophage activity. Anzurstobart enhances macrophage-mediated phagocytosis of diffuse large B-cell lymphoma (DLBCL) cell lines in co-culture with Rituximab, and it shows considerable promise in both solid and hematologic malignancy research, positioning it as a potential candidate for immuno-oncology applications. Target: Others. References: Henry Chan, et al. Discovery and Preclinical Characterization of CC-95251, an Anti-SIRPalpha Antibody That Enhances Macrophage-Mediated Phagocytosis of Non-Hodgkin Lymphoma (NHL) Cells When Combined with Rituximab. Blood (2021) 138 (Supplement 1): 2271.